Enable Injections, Inc. today announced a new single, partial or multi-vial/syringe transfer system for filling its large volume wearable injectors (LVWI)s.
Enable Injections, Inc. is a company that developes advanced LVWI for subcutaneous delivery of biologics and high volume drugs.
The system provides maximum flexibility by allowing the use of single or multiple vials and single or multiple syringes. It can also be used for variable dosing dependent on a patient’s weight.
The new biologics delivery tool has attracted additional development and commercial projects from Enable Injections’ pharmaceutical partners and will be showcased for the first time at the BIO International Convention meeting in San Diego, June 19-22, 2017.
The small hand held Enable multi-vial transfer system can accommodate any pharmaceutical primary container closure. When multiple vials/syringes–or portions of a vial/syringe–are required to administer the prescribed dose, each vial/syringe is easily attached to the Enable Injector with its own screw-on adapter to reduce any chance of contamination.
A second transfer system for mixing and transferring lyophilized formulations or for mixing two liquid formulations is also available, with both vials attached to quickly, simultaneously fill the Enable Injector.
Once filled from one or multiple vials/syringes, the small, lightweight pain- and error-minimizing Enable Injector adheres to the body. With its pressure-sensing capabilities, it comfortably delivers biologic doses as large as 50mL with the push of a button, no needle in sight. Self-administered by patients at home or work, the Enable Injections platform provides an alternative to costly intravenous infusions in a healthcare setting. Also in development by Enable is an app-connected device that is widely expected to lower overall healthcare costs while positively impacting outcomes by boosting compliance.
A presentation on the latest LVWI advances will take place Wednesday, June 21 at 5:00 pm in Company Presentation Theater 1.
SOURCE Enable Injections via Prnewswire